128
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine

, ORCID Icon, , , , , , , , , & show all
Pages 1631-1640 | Published online: 03 May 2021

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30. doi:10.3322/caac.21442
  • Andreoiu M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 2010;41:781–793. doi:10.1016/j.humpath.2010.02.011
  • Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet. 2012;44:685–689. doi:10.1038/ng.2279
  • Fraser M, Sabelnykova VY, Yamaguchi TN, et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature. 2017;541:359–364. doi:10.1038/nature20788
  • Wedge DC, Gundem G, Mitchell T, et al. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet. 2018;50:682–692. doi:10.1038/s41588-018-0086-z
  • Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–282. doi:10.1016/j.eururo.2020.09.046
  • Palermo G, Bassi P, Racioppi M, et al. Circulating tumor cells as prognostic biological marker in different stages prostate cancer and the effect of different therapeutic approaches on their expression. Minerva urologica e nefrologica. 2020;72:214–222. doi:10.23736/S0393-2249.19.03377-0
  • Jiang Z, Zhao Y, Tian Y. Comparison of diagnostic efficacy by two urine PCA3 scores in prostate cancer patients undergoing repeat biopsies. Minerva urologica e nefrologica. 2019;71:373–380. doi:10.23736/S0393-2249.18.03093-X
  • Lovf M, Zhao S, Axcrona U, et al. Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity. Eur Urol. 2019;75(3):498–505. doi:10.1016/j.eururo.2018.08.009
  • Loeb S, Vellekoop A, Ahmed HU, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–892. doi:10.1016/j.eururo.2013.05.049
  • De Paoli-iseppi R, Johansson PA, Menzies AM, et al. Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology. 2016;48:261–266. doi:10.1016/j.pathol.2016.01.001
  • Hognas G, Kivinummi K, Kallio HML, et al. Feasibility of prostate PAXgene fixation for molecular research and diagnostic surgical pathology: comparison of matched fresh frozen, FFPE, and PFPE tissues. Am J Surg Pathol. 2018;42:103–115. doi:10.1097/PAS.0000000000000961
  • Hubner N, Shariat S, Remzi M. Prostate biopsy: guidelines and evidence. Curr Opin Urol. 2018;28:354–359. doi:10.1097/MOU.0000000000000510
  • Shen R, Seshan VE. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res. 2016;44:e131. doi:10.1093/nar/gkw520
  • Roth A, Khattra J, Yap D, et al. PyClone: statistical inference of clonal population structure in cancer. Nat Methods. 2014;11:396–398. doi:10.1038/nmeth.2883
  • Dang HX, White BS, Foltz SM, et al. ClonEvol: clonal ordering and visualization in cancer sequencing. Ann Oncol. 2017;28:3076–3082. doi:10.1093/annonc/mdx517
  • Lindberg J, Klevebring D, Liu W, et al. Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins. Eur Urol. 2013;63:347–353. doi:10.1016/j.eururo.2012.03.050
  • Boutros PC, Fraser M, Harding NJ, et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet. 2015;47:736–745. doi:10.1038/ng.3315
  • Djavan B, Susani M, Bursa B, et al. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol. 1999;5:139–142. doi:10.1016/S0022-5347(01)62084-6
  • Demirtas A, Sonmez G, Tombul ST, et al. Comparison of the upgrading rates of international society of urological pathology grades and tumor laterality in patients undergoing standard 12-core prostate biopsy versus fusion prostate biopsy for prostate cancer. Urol Int. 2019;103:256–261. doi:10.1159/000501528
  • Ruijter ET, van de Kaa CA, Schalken JA, et al. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996;180:295–299. doi:10.1002/(SICI)1096-9896(199611)180:3<295::AID-PATH663>3.0.CO;2-W
  • Arora R, Koch MO, Eble JN, et al. Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate. Cancer. 2004;100:2362–2366. doi:10.1002/cncr.20243
  • Harris WP, Mostaghel EA, Nelson PS, et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85. doi:10.1038/ncpuro1296
  • de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. doi:10.1056/NEJMoa1014618
  • Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197. doi:10.1056/NEJMoa1207506
  • Toren PJ, Gleave ME. Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl. 2013;15:342–349. doi:10.1038/aja.2013.38
  • Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018;36:2492–2503. doi:10.1200/JCO.2017.77.6880
  • Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes: figure 1. Cancer Discov. 2011;1:466–468. doi:10.1158/2159-8290.CD-11-0259
  • Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 2011;1:487–495. doi:10.1158/2159-8290.CD-11-0130
  • Aparicio AM, Shen L, Tapia EL, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22:1520–1530. doi:10.1158/1078-0432.CCR-15-1259
  • Tan HL, Sood A, Rahimi HA, et al. Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma. Clin Cancer Res. 2014;20:890–903. doi:10.1158/1078-0432.CCR-13-1982
  • Tsai H, Morais CL, Alshalalfa M, et al. Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res. 2015;21:5619–5629. doi:10.1158/1078-0432.CCR-15-0744
  • Kronig M, Nanko N, Drendel V, et al. Single punch, double biopsy. SpringerPlus. 2016;5:1456. doi:10.1186/s40064-016-3141-1
  • Sonmez G, Tombul ST, Demirtas T, et al. Risk factors associated with pain in fusion prostate biopsy. Prostate Int. 2020;8:185–189. doi:10.1016/j.prnil.2020.05.004